{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:52:05Z","timestamp":1794455525905,"version":"4.9.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-04985-1","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T10:14:06Z","timestamp":1781086446000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TACE, lenvatinib, and PD-1 inhibitors in unresectable advanced hepatocellular carcinoma: an exploratory retrospective cohort study"],"prefix":"10.1186","volume":"26","author":[{"given":"Hongyi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miaomiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"4985_CR1","doi-asserted-by":"crossref","unstructured":"Ali AAK, Gamal SE, Anwar R, Elzahaf E, Eskandere DJTEJIM. Assessment of clinico-epidemiological profile of Hepatocellular carcinoma in the last two decades. The Egyptian Journal of Internal Medicine. 2023;35(1):18.","DOI":"10.1186\/s43162-023-00201-8"},{"key":"4985_CR2","doi-asserted-by":"publisher","first-page":"1325992","DOI":"10.3389\/fphar.2023.1325992","volume":"14","author":"S Guo","year":"2023","unstructured":"Guo S, Xing N, Du Q, Luo B, Wang S. Deciphering hepatocellular carcinoma pathogenesis and therapeutics: a study on anoikis, ceRNA regulatory network and traditional Chinese medicine. Front Pharmacol. 2023;14:1325992.","journal-title":"Front Pharmacol"},{"key":"4985_CR3","doi-asserted-by":"publisher","first-page":"985191","DOI":"10.3389\/fgene.2022.985191","volume":"13","author":"J Wang","year":"2022","unstructured":"Wang J, Shen B, Liu X, Jiang J. A novel necroptosis-related lncRNA signature predicts the prognosis and immune microenvironment of hepatocellular carcinoma. Front Genet. 2022;13:985191.","journal-title":"Front Genet"},{"issue":"10","key":"4985_CR4","doi-asserted-by":"publisher","first-page":"11513","DOI":"10.1002\/cam4.5880","volume":"12","author":"WJ Wang","year":"2023","unstructured":"Wang WJ, Liu ZH, Wang K, Yu HM, Cheng YQ, Xiang YJ, et al. Efficacy and safety of TACE combined with lenvatinib and PD-1 inhibitors for unresectable recurrent HCC: A multicenter, retrospective study. Cancer Med. 2023;12(10):11513\u201324.","journal-title":"Cancer Med"},{"key":"4985_CR5","first-page":"91","volume-title":"The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma","author":"QQ Liu","year":"2024","unstructured":"Liu QQ, Wang XX, Ji H, Dou QY, Zhang HM. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma. Volume 41. London, England: Medical oncology (Northwood; 2024. p. 91. 5."},{"key":"4985_CR6","doi-asserted-by":"crossref","unstructured":"Wang S, Wang Y, Yu J, Wu H, Zhou Y. Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Cancers. 2022;14(22):5525.","DOI":"10.3390\/cancers14225525"},{"issue":"1","key":"4985_CR7","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/MEG.0000000000002668","volume":"36","author":"X Hua","year":"2024","unstructured":"Hua X, Yin Z, Liang J, Chen W, Gong H. Efficacy and safety comparison between Lenvatinib and Sorafenib in hepatocellular carcinoma treatment: a systematic review and meta-analysis of real-world study. Eur J Gastroenterol Hepatol. 2024;36(1):120\u20138.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"6","key":"4985_CR8","doi-asserted-by":"publisher","first-page":"2641","DOI":"10.1002\/cam4.1517","volume":"7","author":"M Matsuki","year":"2018","unstructured":"Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, et al. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018;7(6):2641\u201353.","journal-title":"Cancer Med"},{"issue":"1","key":"4985_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","volume":"55","author":"T Yamashita","year":"2020","unstructured":"Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, et al. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset. J Gastroenterol. 2020;55(1):113\u201322.","journal-title":"J Gastroenterol"},{"key":"4985_CR10","doi-asserted-by":"crossref","unstructured":"Hill SL, Elliott TJ, Johnson PWJTB. A commentary on the Nobel Prize award for Physiology or Medicine\u2013for the discovery of cancer therapy by inhibition of negative immune regulation. The Biochemist. 2019;41(1):4\u20137.","DOI":"10.1042\/BIO04101004"},{"key":"4985_CR11","doi-asserted-by":"crossref","unstructured":"Gravbrot N, Gilbert-Gard K, Mehta P, Ghotmi Y, Banerjee M, Mazis C et al. Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors. Antibodies (Basel Switzerland). 2019;8(4):51.","DOI":"10.3390\/antib8040051"},{"issue":"10088","key":"4985_CR12","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","volume":"389","author":"AB El-Khoueiry","year":"2017","unstructured":"El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1\/2 dose escalation and expansion trial. Lancet (London England). 2017;389(10088):2492\u2013502.","journal-title":"Lancet (London England)"},{"key":"4985_CR13","doi-asserted-by":"publisher","first-page":"175883592110311","DOI":"10.1177\/17588359211031141","volume":"13","author":"C Hsu","year":"2021","unstructured":"Hsu C, Rimassa L, Sun HC, Vogel A, Kaseb AO. Immunotherapy in hepatocellular carcinoma: evaluation and management of adverse events associated with atezolizumab plus bevacizumab. Therapeutic Adv Med Oncol. 2021;13:17588359211031141.","journal-title":"Therapeutic Adv Med Oncol"},{"key":"4985_CR14","doi-asserted-by":"publisher","first-page":"1070961","DOI":"10.3389\/fimmu.2022.1070961","volume":"13","author":"Q Li","year":"2022","unstructured":"Li Q, Han J, Yang Y, Chen Y. PD-1\/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy. Front Immunol. 2022;13:1070961.","journal-title":"Front Immunol"},{"issue":"3","key":"4985_CR15","doi-asserted-by":"publisher","first-page":"340","DOI":"10.4103\/tcmj.tcmj_159_23","volume":"36","author":"TR Peng","year":"2024","unstructured":"Peng TR, Yang LJ, Wu TW. Efficacy of PD-1\/PD-L1 inhibitors in advanced hepatocellular carcinoma: A systematic review and meta-analysis. Tzu chi Med J. 2024;36(3):340\u20138.","journal-title":"Tzu chi Med J"},{"key":"4985_CR16","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.2147\/JHC.S443041","volume":"10","author":"B Gao","year":"2023","unstructured":"Gao B, Yang F, Zheng D, Hu S, Liu J, Liu H, et al. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. J hepatocellular carcinoma. 2023;10:2265\u201376.","journal-title":"J hepatocellular carcinoma"},{"issue":"26","key":"4985_CR17","doi-asserted-by":"publisher","first-page":"e2300906","DOI":"10.1002\/adhm.202300906","volume":"12","author":"H Kim","year":"2023","unstructured":"Kim H, Choi B, Mouli SK, Choi H, Harris KR, Kulik LM, et al. Preclinical Development and Validation of Translational Temperature Sensitive Iodized Oil Emulsion Mediated Transcatheter Arterial Chemo-Immuno-Embolization for the Treatment of Hepatocellular Carcinoma. Adv Healthc Mater. 2023;12(26):e2300906.","journal-title":"Adv Healthc Mater"},{"key":"4985_CR18","doi-asserted-by":"crossref","unstructured":"Marinelli B, Kim E, D\u2019Alessio A, Cedillo M, Sinha I, Debnath N et al. Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study. J Immunother Cancer. 2022;10(6):e004205.","DOI":"10.1136\/jitc-2021-004205"},{"issue":"3","key":"4985_CR19","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1159\/000505695","volume":"9","author":"H Deng","year":"2020","unstructured":"Deng H, Kan A, Lyu N, Mu L, Han Y, Liu L, et al. Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma. Liver cancer. 2020;9(3):338\u201357.","journal-title":"Liver cancer"},{"issue":"3","key":"4985_CR20","doi-asserted-by":"publisher","first-page":"245","DOI":"10.3350\/cmh.2018.0090","volume":"25","author":"TH Kim","year":"2019","unstructured":"Kim TH, Kim SY, Tang A, Lee JM. Comparison of international guidelines for noninvasive diagnosis of hepatocellular carcinoma: 2018 update. Clin Mol Hepatol. 2019;25(3):245\u201363.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"4985_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):52\u201360.","journal-title":"Semin Liver Dis"},{"issue":"1","key":"4985_CR22","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas dermo-sifiliograficas. 2021;112(1):90\u20132.","journal-title":"Actas dermo-sifiliograficas"},{"key":"4985_CR23","doi-asserted-by":"publisher","first-page":"1446030","DOI":"10.3389\/fphar.2024.1446030","volume":"15","author":"X Wang","year":"2024","unstructured":"Wang X, Yang Y, Zhao S, Wu D, Li L, Zhao Z. Chitosan-based biomaterial delivery strategies for hepatocellular carcinoma. Front Pharmacol. 2024;15:1446030.","journal-title":"Front Pharmacol"},{"key":"4985_CR24","doi-asserted-by":"crossref","unstructured":"Posa A, Contegiacomo A, Ponziani FR, Punzi E, Mazza G, Scrofani A et al. Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends. Int J Mol Sci. 2023;24(8):7344.","DOI":"10.3390\/ijms24087344"},{"issue":"5","key":"4985_CR25","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/hep.30337","volume":"69","author":"MJ Flynn","year":"2019","unstructured":"Flynn MJ, Sayed AA, Sharma R, Siddique A, Pinato DJ. Challenges and Opportunities in the Clinical Development of Immune Checkpoint Inhibitors for Hepatocellular Carcinoma. Hepatology (Baltimore MD). 2019;69(5):2258\u201370.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"3","key":"4985_CR26","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00262-025-03962-z","volume":"74","author":"Z Ren","year":"2025","unstructured":"Ren Z, Wang Y, Jiang D, Liu Y, Yang X, Wang T, et al. PD1(+) Treg cell remodeling promotes immune homeostasis within peripheral blood and tumor microenvironment after microparticles-transarterial chemoembolization in hepatocellular carcinoma. Cancer Immunol immunotherapy: CII. 2025;74(3):109.","journal-title":"Cancer Immunol immunotherapy: CII"},{"issue":"1","key":"4985_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43046-023-00186-z","volume":"35","author":"S Bandopadhyay","year":"2023","unstructured":"Bandopadhyay S, Patranabis S. Mechanisms of HIF-driven immunosuppression in tumour microenvironment. J Egypt Natl Cancer Inst. 2023;35(1):27.","journal-title":"J Egypt Natl Cancer Inst"},{"key":"4985_CR28","doi-asserted-by":"publisher","first-page":"e11306","DOI":"10.7717\/peerj.11306","volume":"9","author":"M Hu","year":"2021","unstructured":"Hu M, Li Y, Lu Y, Wang M, Li Y, Wang C, et al. The regulation of immune checkpoints by the hypoxic tumor microenvironment. PeerJ. 2021;9:e11306.","journal-title":"PeerJ"},{"key":"4985_CR29","doi-asserted-by":"crossref","unstructured":"Zhong C, Niu Y, Liu W, Yuan Y, Li K, Shi Y et al. S100A9 Derived from Chemoembolization-Induced Hypoxia Governs Mitochondrial Function in Hepatocellular Carcinoma Progression. Advanced science (Weinheim, Baden-Wurttemberg, Germany). 2022;9(30):e2202206.","DOI":"10.1002\/advs.202202206"},{"issue":"12","key":"4985_CR30","doi-asserted-by":"publisher","first-page":"3993","DOI":"10.1111\/cas.13806","volume":"109","author":"T Kimura","year":"2018","unstructured":"Kimura T, Kato Y, Ozawa Y, Kodama K, Ito J, Ichikawa K, et al. Immunomodulatory activity of lenvatinib contributes to antitumor activity in the Hepa1-6 hepatocellular carcinoma model. Cancer Sci. 2018;109(12):3993\u20134002.","journal-title":"Cancer Sci"},{"key":"4985_CR31","doi-asserted-by":"publisher","first-page":"1212577","DOI":"10.3389\/fimmu.2023.1212577","volume":"14","author":"J Yang","year":"2023","unstructured":"Yang J, Guo Z, Song M, Pan Q, Zhao J, Huang Y, et al. Lenvatinib improves anti-PD-1 therapeutic efficacy by promoting vascular normalization via the NRP-1-PDGFR\u03b2 complex in hepatocellular carcinoma. Front Immunol. 2023;14:1212577.","journal-title":"Front Immunol"},{"key":"4985_CR32","doi-asserted-by":"crossref","unstructured":"Ac\u00farcio RC, Pozzi S, Carreira B, Pojo M, G\u00f3mez-Cebri\u00e1n N, Casimiro S et al. Therapeutic targeting of PD-1\/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T cells into solid tumor microenvironment. J Immunother Cancer. 2022;10(7): e004695.","DOI":"10.1136\/jitc-2022-004695"},{"issue":"9","key":"4985_CR33","first-page":"4135","volume":"27","author":"C Chen","year":"2023","unstructured":"Chen C, Duan XT, Li GY, Hao XJ, Wang WL, Shen YF, et al. Evaluation of the efficacy of aparatinib and carrilizumab combined with transcatheter arterial chemoembolization in the treatment of primary hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2023;27(9):4135\u201344.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"4985_CR34","doi-asserted-by":"publisher","first-page":"874473","DOI":"10.3389\/fonc.2022.874473","volume":"12","author":"S Qu","year":"2022","unstructured":"Qu S, Zhang X, Wu Y, Meng Y, Pan H, Fang Q, et al. Efficacy and Safety of TACE Combined With Lenvatinib Plus PD-1 Inhibitors Compared With TACE Alone for Unresectable Hepatocellular Carcinoma Patients: A Prospective Cohort Study. Front Oncol. 2022;12:874473.","journal-title":"Front Oncol"},{"issue":"4","key":"4985_CR35","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1159\/000535154","volume":"13","author":"M Kudo","year":"2024","unstructured":"Kudo M, Finn RS, Ikeda M, Sung MW, Baron AD, Okusaka T, et al. A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116. Liver cancer. 2024;13(4):451\u20138.","journal-title":"Liver cancer"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-04985-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-04985-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:02:49Z","timestamp":1786921369000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-04985-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4985"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-04985-1","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"8 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki. Ethical approval was obtained from Institutional Review Board of Beijing Shijitan Hospital Affiliated to Capital Medical University (Approval No. IIT2024-106-001) with waiver of informed consent granted for retrospective anonymized data analysis.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"508"}}